Bronchial croup in children is a common disease that seriously endangers children’s health, and there are nearly 10 million children with asthma in China, but the current rate of children receiving standardized treatment is low, and asthma in children is far more under-treated than over-treated. In addition to the familiar wheezing episodes, the manifestations of uncontrolled asthma can also manifest as frequent colds, difficulty in curing each cold, or the appearance of a long-term cough. Children with recurrent cough should be alerted to asthma, especially with wheezing, family history of asthma and personal history of allergies (eczema, allergic rhinitis, hives, etc.), should be highly suspected of asthma and should be further examined for early diagnosis. The treatment of asthma in children should adhere to the principles of long-term, continuous, standardized and individualized treatment. Treatment needs to be continued for a long period of time and discontinuation of medication should be avoided Asthma is a heterogeneous disease characterized by chronic airway inflammation and airway hyperresponsiveness. It is a chronic disease with recurrent attacks, and treatment during the remission period is very important. Only by adhering to long-term standardized treatment can airway inflammation be completely eliminated and asthma be completely controlled, and parents should not arbitrarily reduce or stop medication when they see that their child’s condition is stable without attacks. In clinical practice, appropriate drugs and suitable drug delivery methods should be selected for long-term standardized treatment according to the condition and age of the child. Select the appropriate inhalation drug device according to the age characteristics The commonly used inhalation devices are: pressurized quantitative aerosol, dry powder inhaler, and nebulizer inhaler. The choice of inhalation device is mainly based on the age of the child and the severity of the disease. Pressure dosing aerosols are suitable for children of all ages, but children under 5 years of age should be combined with a storage canister to assist with inhalation. Dry powder inhalers require a strong inhalation force and are most suitable for children older than 5 years old, but they must be taught repeatedly how to use them before use. Both pressurized dosing aerosols and dry powder inhalers are not suitable for the more severe cases. Nebulized inhalation requires little coordination from the child and is indicated for infants, uncooperative older children, and children with severe exacerbations. Don’t hesitate to use inhaled glucocorticosteroids, there is no need to talk about hormones Inhaled glucocorticosteroids (ICS), which are currently the most effective drugs for controlling airway inflammation, are available as beclomethasone propionate, budesonide and fluticasone, inhaled as a quantitative aerosol, dry powder or solution. The level of asthma control has a dose-effect relationship with inhaled therapeutic drugs, and usually the higher the dose the better the control. When ICS is started, a higher dose is usually given for rapid control of asthma symptoms, which can be gradually reduced to the lowest maintenance dose after 3-6 months. For seasonal asthma, ICS can be given 2 weeks before the season arrives and then discontinued after the season. Adherence to ICS as prescribed and inhalation of the short-acting beta agonist, salbutamol, as needed (during acute attacks) can lead to complete and good control in most patients with mild to moderate asthma. Some parents are fearful of glucocorticoids and fear that long-term use will affect their children’s growth and development, thus not regulating or refusing to apply them. In fact, inhaled hormones are very different from the systemic hormones (such as prednisone and dexamethasone) that we commonly use. The daily dosage for children is only 200-400 micrograms, which is 100 times smaller than the dosage of systemic hormones, and only 20% of the inhaled hormones enter the blood circulation. GINA guidelines state that if low-dose inhaled corticosteroids (ICS) achieve asthma control and there are no symptomatic episodes for 1 year, consider discontinuing the drug for observation. For moderate asthma and above, it takes 2 years from the start of treatment to asthma control, and another 1 year of symptom-free inhalation at the lowest dose, for a total course of at least 3 years. Avoid discontinuation in the presence of climate change, respiratory infections, etc. <6 years old asthma: high percentage of natural remission, at least two assessments per year, stable disease after 3-6 months of control therapy, can be considered for discontinuation and observation; relapse treatment regimen after discontinuation: depends on severity and frequency of attacks, occasional mild symptoms treated symptomatically continue discontinuation and observation, non-frequent general wheezing attacks revert to the pre-discontinuation regimen, severe and/or frequent attacks should be Severe and/or frequent episodes should be upgraded or overtaken on the basis of the pre-discontinuation regimen.